loading
前日終値:
$7.30
開ける:
$7.3
24時間の取引高:
1.42M
Relative Volume:
0.74
時価総額:
$2.29B
収益:
$2.68B
当期純損益:
$-184.45M
株価収益率:
-10.76
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
+2.23%
1か月 パフォーマンス:
-5.55%
6か月 パフォーマンス:
-11.49%
1年 パフォーマンス:
+7.96%
1日の値動き範囲:
Value
$7.19
$7.385
1週間の範囲:
Value
$7.19
$7.385
52週間の値動き範囲:
Value
$6.29
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
名前
Amneal Pharmaceuticals Inc
Name
セクター
Healthcare (1170)
Name
電話
908-947-3120
Name
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
職員
5,210
Name
Twitter
@amnealpharma
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
AMRX's Discussions on Twitter

AMRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
7.32 2.24B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.35 50.14B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
168.63 72.38B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.79 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 45.51B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.78 19.45B 16.54B -1.64B 749.00M -1.45

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 アップグレード JP Morgan Neutral → Overweight
2024-09-06 アップグレード JP Morgan Underweight → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2021-03-08 アップグレード Goldman Sell → Buy
2020-12-14 アップグレード Barclays Equal Weight → Overweight
2020-12-14 アップグレード Guggenheim Neutral → Buy
2020-07-27 開始されました Goldman Sell
2020-05-12 アップグレード Guggenheim Sell → Neutral
2019-12-12 ダウングレード Raymond James Outperform → Mkt Perform
2019-11-12 ダウングレード JP Morgan Neutral → Underweight
2019-11-07 ダウングレード SVB Leerink Outperform → Mkt Perform
2019-07-22 アップグレード SVB Leerink Mkt Perform → Outperform
2019-07-11 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-07-08 アップグレード Piper Jaffray Neutral → Overweight
2019-06-11 開始されました Barclays Equal Weight
2019-05-21 アップグレード Raymond James Mkt Perform → Strong Buy
2019-03-20 開始されました SunTrust Buy
2019-03-08 ダウングレード SVB Leerink Outperform → Mkt Perform
2018-12-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2018-10-16 ダウングレード SunTrust Buy → Hold
2018-08-13 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-07-23 開始されました Morgan Stanley Overweight
2018-06-22 開始されました B. Riley FBR, Inc. Buy
すべてを表示

Amneal Pharmaceuticals Inc (AMRX) 最新ニュース

pulisher
May 29, 2025

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 29, 2025
pulisher
May 28, 2025

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Pharyngitis Treatment Market with Antibiotics and Home - openPR.com

May 27, 2025
pulisher
May 26, 2025

3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 26, 2025
pulisher
May 22, 2025

Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com

May 22, 2025
pulisher
May 22, 2025

Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire

May 21, 2025
pulisher
May 20, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 20, 2025
pulisher
May 19, 2025

Ameriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 19, 2025
pulisher
May 16, 2025

Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN

May 16, 2025
pulisher
May 16, 2025

US FDA approves Amneal's self-administered migraine treatment - Reuters

May 16, 2025
pulisher
May 16, 2025

AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Amneal Gets FDA Nod For Self-Administrable Migraine Injection - MSN

May 16, 2025
pulisher
May 16, 2025

The Manufacturers Life Insurance Company Has $689,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 16, 2025
pulisher
May 16, 2025

Amneal gets FDA approval for Brekiya to treat migraine and cluster headaches - World Pharmaceutical Frontiers

May 16, 2025
pulisher
May 16, 2025

Amneal’s Brekiya autoinjector approved by FDA for migraines - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Northern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 16, 2025
pulisher
May 15, 2025

Amneal’s Brekiya autoinjector approved by FDA for migraines By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

Amneal Gets FDA Nod For Self-Administrable Migraine Injection By Stocktwits - Investing.com India

May 15, 2025
pulisher
May 15, 2025

FDA Approves Amneal's (AMRX) Brekiya Autoinjector for Migraine R - GuruFocus

May 15, 2025
pulisher
May 15, 2025

US FDA approves Amneal’s self-administered migraine treatment - 1470 & 100.3 WMBD

May 15, 2025
pulisher
May 15, 2025

FDA Greenlights Amneal's (AMRX) Innovative Migraine Treatment | AMRX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Amneal Pharmaceuticals' Brekiya Approved by FDA - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Amneal rises after US FDA greenlights self-administered migraine treatment - TradingView

May 15, 2025
pulisher
May 15, 2025

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - The Manila Times

May 15, 2025
pulisher
May 15, 2025

US FDA approves Amneal's migraine treatment - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Amneal Receives U.S. FDA Approval for Brekiya® - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Breakthrough: First At-Home Injectable Migraine Treatment Gets FDA Green LightWhat Makes It Different - Stock Titan

May 15, 2025
pulisher
May 15, 2025

This Insider Has Just Sold Shares In Amneal Pharmaceuticals - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by StockNews.com - Defense World

May 15, 2025
pulisher
May 13, 2025

Director John Kiely Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 13, 2025
pulisher
May 12, 2025

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing - insights.citeline.com

May 12, 2025
pulisher
May 12, 2025

Key Trends Shaping the Future of Filgrastim Biosimilars Market: Amneal Pharmaceuticals' Fylnetra Marks A Ne... - WhaTech

May 12, 2025
pulisher
May 10, 2025

Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - MSN

May 10, 2025
pulisher
May 10, 2025

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease - Business Wire

May 10, 2025
pulisher
May 09, 2025

Amneal Pharmaceuticals to add 200 jobs at its Brookhaven factory - Newsday

May 09, 2025
pulisher
May 09, 2025

Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Amneal and Apiject join forces to boost US pharmaceutical manufacturing - World Pharmaceutical Frontiers

May 09, 2025
pulisher
May 09, 2025

Decoding Amneal Pharmaceuticals Inc (AMRX): A Strategic SWOT Ins - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks

May 08, 2025
pulisher
May 08, 2025

Here is Why Growth Investors Should Buy Amneal (AMRX) Now - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Are Options Traders Betting On A Big Move In Amneal Pharmaceuticals Stock? - Barchart.com

May 08, 2025
pulisher
May 08, 2025

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced ... - Bluefield Daily Telegraph

May 08, 2025

Amneal Pharmaceuticals Inc (AMRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_specialty_generic RGC
$877.00
price up icon 18.36%
drug_manufacturers_specialty_generic HCM
$13.89
price up icon 0.22%
$123.02
price down icon 0.52%
drug_manufacturers_specialty_generic RDY
$14.72
price down icon 0.20%
$318.85
price down icon 0.47%
$16.78
price down icon 4.28%
大文字化:     |  ボリューム (24 時間):